Ianalumab阻断BAFF受体治疗中重度系统性红斑狼疮的2期随机双盲安慰剂对照试验
这项2期随机双盲安慰剂对照试验评估了靶向BAFF受体的单克隆抗体ianalumab治疗活动性SLE的疗效与安全性。
要点
- ianalumab组第28周主要复合终点应答率44.1%,显著高于安慰剂组9.1%。
- 疗效在SRI-6、DORIS、LLDAS、 flare减少及激素使用等指标上一致显现,持续至第52周。
- 未增加严重不良事件或严重感染,非严重注射部位反应更常见。
核心结论
- 在标准治疗基础上加用ianalumab可降低中重度SLE患者第28周疾病活动度,并持续获益至1年,耐受性良好。
主要发现
- 第28周主要复合终点(SRI-4且成功减停激素)ianalumab组15/34(44.1%)vs 安慰剂组3/33(9.1%)。
- 应答持续至第52周,安慰剂转开放标签ianalumab后应答率分别为15/33(45.5%)和13/32(40.6%)。
- SRI-6、DORIS、LLDAS、flare减少及激素使用等指标在第28周一致显示积极治疗效果,临床获益持续至第52周和第68周。
- ianalumab未增加严重不良事件或严重感染,非严重注射部位局部反应更常见。
临床怎么用
- 对于活动性中重度SLE且标准治疗应答不佳的患者,ianalumab联合标准治疗可能提高第28周复合应答率并持续控制疾病活动。
- 治疗期间需关注注射部位反应,但严重感染和严重不良事件风险未见增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: B cell depletion or B cell activating factor (BAFF) blockade has shown benefits in systemic lupus erythematosus (SLE). We compared ianalumab, a monoclonal antibody targeting BAFF receptor (BAFF-R)-expressing B cells to lyse B cells and block BAFF-R, with placebo for SLE treatment combined with standard therapies. METHODS: Patients with active SLE were randomised (1:1) to monthly subcutaneous ianalumab 300 mg or placebo. The primary outcome was a composite of SLE Responder Index (SRI)-4 at week 28 in patients successfully achieving corticosteroid (CS) tapering criteria. Patients subsequently received open-label (OL) ianalumab until week 48, followed by exploratory assessments at week 52 and off-treatment to week 68. Safety monitoring continued until B cell recovery. This report describes interim analyses conducted on the week 68 dataset. RESULTS: Sixty-seven patients were randomised and received blinded treatments until week 28. The primary composite endpoint was more frequently achieved with ianalumab vs placebo: 15/34 (44.1%) vs 3/33 (9.1%), with responses sustained to week 52 and replicated by placebo transitioned to OL ianalumab: 15/33 (45.5%) and 13/32 (40.6%). Positive treatment effects were consistently observed across other lupus disease activity outcomes (SRI-6, Definition of Remission in SLE, Lupus Low Disease Activity State, flare reduction, and CS use) at week 28, with clinical benefits until weeks 52 and 68. Ianalumab was not associated with increased serious adverse events or serious infections. Nonserious local injection site reactions occurred more frequently with ianalumab. CONCLUSIONS: At week 28, reduced disease activity was observed in patients with SLE receiving ianalumab plus standard therapies compared with those receiving standard therapies alone, with sustained benefits with further treatment until 1 year, which was well tolerated.
引用
- Agmon-Levin N, Ignatenko S, Gordienko A, et al. B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment. Ann Rheum Dis. 2025. PMID: 41353079. doi:10.1016/j.ard.2025.11.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。